Suppr超能文献

受磷蛋白与心脏收缩力

Phospholamban and cardiac contractility.

作者信息

Frank K, Kranias E G

机构信息

Department of Pharmacology and Cell Biophysics, University of Cincinnati, College of Medicine, OH 45267-0575, USA.

出版信息

Ann Med. 2000 Nov;32(8):572-8. doi: 10.3109/07853890008998837.

Abstract

Over the last three decades, our knowledge and understanding of the role of phospholamban and its modulation of sarcoplasmic reticulum (SR) function has advanced significantly. Phospholamban is a key regulator of cardiac contractility and modulates SR Ca2+ sequestration by inhibiting the SR Ca2+-ATPase (SERCA) in its dephosphorylated state. Upon phosphorylation, which is mediated through beta-adrenergic stimulation, the inhibitory effect of phospholamban on the function of SERCA is relieved. This review summarizes recent advances that have been made towards understanding the modulation of SR Ca2+-sequestration by phospholamban through the generation and characterization of genetically altered animal models. It also discusses the role of phospholamban in human heart failure and recent attempts to restore SR function in experimentally induced and human heart failure, which may be translated into future therapeutic approaches in the treatment of this disease.

摘要

在过去三十年中,我们对受磷蛋白及其对肌浆网(SR)功能调节作用的认识和理解有了显著进展。受磷蛋白是心脏收缩力的关键调节因子,在其去磷酸化状态下通过抑制肌浆网Ca2+ -ATP酶(SERCA)来调节肌浆网Ca2+ 的摄取。通过β - 肾上腺素能刺激介导的磷酸化作用,可解除受磷蛋白对SERCA功能的抑制作用。本综述总结了通过构建和鉴定基因改变动物模型,在理解受磷蛋白对肌浆网Ca2+ 摄取调节方面取得的最新进展。还讨论了受磷蛋白在人类心力衰竭中的作用,以及最近在实验诱导的和人类心力衰竭中恢复肌浆网功能的尝试,这些尝试可能会转化为治疗该疾病的未来治疗方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验